Biopharmaceutical company: AgeX Therapeutics (AGE)

AgeX Therapeutics, Inc. (AMEX:AGE) was founded in 2017 and is headquartered in Alameda, California. It was operated independently from BioTime, Inc. (AMEX:BTX TASE:BTX) on November 28, 2018. It is a biotechnology company , Focusing on the development and commercialization of treatments for age-related degenerative diseases in the United States.

AgeX Therapeutics

AgeX Therapeutics (AGE):

AgeX Therapeutics focuses on the development and commercialization of new treatments for human aging. AgeX Therapeutics is building on the company’s proprietary technologies, such as PureStem ® and induced Tissue Regeneration (iTR™), to develop innovative drugs aimed at solving some of the biggest unsolved problems in aging.

Through PureStem ® , the company can generate any type of young cells derived from pluripotent stem cells for potential applications in a series of degenerative aging diseases, with high unmet medical needs. iTR™ is AgeX Therapeutics’ revolutionary life extension platform, designed to release cell immortality and regeneration capabilities to reverse the age-related changes in the body.

PureStem ® derived cell therapy candidates developed by AgeX Therapeutics include AGEX-VASC1 and AGEX-BAT1:

  1. AGEX-VASC1 -is a pre-clinical cell-based therapy, composed of vascular endothelial progenitor cells, used to restore vascular support in ischemic tissues.
  2. AGEX-BAT1 -a preclinical cell therapy candidate for adipocytes used by the company to treat certain age-related metabolic disorders (such as type II diabetes).

The iTR™ drug-based therapeutic candidates developed by AgeX Therapeutics include AGEX-iTR1547 and Renelon™:

  1. AGEX-iTR1547-is a drug-based pre-clinical development formula designed to use the company’s proprietary iTR™ technology to restore the regenerative potential of various elderly tissues suffering from degenerative diseases.
  2. Renelon™-is the first-generation iTR™ candidate product, designed to promote scar-free tissue repair, and is planned to be developed as a commercial device for topical use.

In addition, AgeX Therapeutics, Inc. sells genome interpretation algorithms; and Cytiva, including cardiomyocytes derived from pluripotent stem cells, for screening drugs for efficacy and safety.

Notify of
Inline Feedbacks
View all Intels

American biopharmaceutical company: Synageva BioPharma (GEVA)-delisting (1996)

Molecular Diagnostics Company: Biocept, Inc. (BIOC) (1997)